In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysisJuly 07, 2016
[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.
Oncology nurses are in an ideal position to educate patients with gastrointestinal malignancies and PVT about risk factors, clinical presentation, complications, and treatment options to prevent further extension of the clot.
An interdisciplinary collaboration between prominent academic and industry investigators discovered a novel method for repositioning an FDA-approved anticancer compound so it can specifically target liver cancer tumors.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Patients undergoing oncologic liver surgeries who participated in an enhanced recovery program returned sooner to their normal life function and to adjuvant cancer therapies than patients who were treated with a traditional approach to perioperative care.
Results of a meta-analysis shows reduction in rate of infection and shorter length of hospital stay with receipt of prebiotics and probiotics before surgery.
Women with intrahepatic cholestasis of pregnancy (ICP) are at increased risk of hepatobiliary cancer.
The risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is increased in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Livers donated to cancer patients by individuals that died of cardiac death do not yield outcomes worse than those donated by people dying from brain death.
Significant clinical variations have been identified among patients with hepatocellular carcinoma (HCC).
Patients with liver cancer have the same positive outcomes using organs donated by patients who died as a result of cardiac death.
A surgical approach in which less than one lobe of the liver is removed in a patient undergoing resection for liver cancer is linked to lowered mortality and complication rates, according to new study results.
The amount of alcohol a person has to drink to risk developing liver cancer has been narrowed down.
The risk of disease recurrence in liver cancer patients who have undergone a liver transplant can now be more accurately calculated, thanks to new tool.
An interventional x-ray guidance device approved by the U.S. Food and Drug Administration in 2013 may have the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer.
Triclosan, a popular antimicrobial agent in soaps, detergents, and plastics, has been found to promote liver cancer in mice.
Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.
Patients that have inoperable advanced hepatocellular carcinoma (HCC) may live significantly longer by receiving a combined therapy, according to recent trial results.
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.
An over-the-counter pill for treating malaria has been found to both prevent liver cancer and shrink existing tumors, according to recent research.
Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to new research.
No considerable survival difference found between patients receiving everolimus and those receiving a placebo.
Lifestyle factors such as overeating, smoking, drinking too much and not enough exercises may be to blame for a sharp rise in liver and skin cancer cases.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|